| Molecular subtyping of triple negative breast cancer by surrogate immunohistochemistry markers S Kumar, A Bal, A Das, S Bhattacharyya, I Laroiya, S Khare, G Singh Applied Immunohistochemistry & Molecular Morphology 29 (4), 251-257, 2021 | 19 | 2021 |
| Tumour angiogenesis and c‐Met pathway activation–implications in breast cancer S Mitra, A Bal, D Kashyap, S Kumar, S Shrivastav, A Das, G Singh Apmis 128 (4), 316-325, 2020 | 17 | 2020 |
| Estrogen receptor beta 1: a potential therapeutic target for female triple negative breast cancer P Dey, A Wang, Y Ziegler, S Kumar, S Yan, SH Kim, JA Katzenellenbogen, ... Endocrinology 163 (12), bqac172, 2022 | 14 | 2022 |
| Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer S Kumar, A Bal, A Das, I Loriya, S Khare, S Bhattacharya, G Singh Breast Cancer Research and Treatment 187 (3), 625-633, 2021 | 14 | 2021 |
| ALK-negative anaplastic large cell lymphoma (ALCL): prognostic implications of molecular subtyping and JAK-STAT pathway M Parkhi, A Bal, A Das, D Kashyap, S Bhardwaj, G Prakash, P Malhotra Applied Immunohistochemistry & Molecular Morphology 29 (9), 648-656, 2021 | 10 | 2021 |
| Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs VS Guillen, Y Ziegler, C Gopinath, S Kumar, P Dey, BN Plotner, ... Breast Cancer Research and Treatment 198 (3), 607-621, 2023 | 9 | 2023 |
| Expression of proteinase-activated receptor 2 (PAR2) as a correlate of concern in triple-negative breast cancer (TNBC) G Kapatia, S Kaur, S Kumar, I Laroiya, G Singh, M Sharma, A Bal, ... Applied Immunohistochemistry & Molecular Morphology 30 (6), 446-452, 2022 | 8 | 2022 |
| Assessment of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) across molecular subtypes of triple-negative breast cancer R Sood, S Kumar, I Laroiya, S Khare, A Das, G Singh, A Bal The breast journal, 2020 | 6 | 2020 |
| Rosette-forming and papillary glioneuronal tumors–A clinicopathological and molecular analysis V Singh, K Gupta, P Salunke, S Kumar, BD Radotra, RK Vasishta Clinical Neuropathology 38 (4), 180, 2019 | 6 | 2019 |
| Assessment of Physicochemical and Bacteriological Parameters of Sukhna Lake in Chandigarh, India AB JyotiDadwal, S Kumar Int. J. Sci. Res (IJSR) 3 (9), 2014 | 6 | 2014 |
| In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines S Kumar, S Bhattacharyya, A Das, G Singh, A Bal Breast Disease 41 (1), 241-247, 2022 | 4 | 2022 |
| Breast cancer stem cell population in different molecular subtypes of breast cancer P Gupta, V Singh, S Kumar, A Das, G Singh, A Bal Breast Disease 41 (1), 199-203, 2022 | 4 | 2022 |
| Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death S Kumar, Y Ziegler, BN Plotner, KM Flatt, SH Kim, JA Katzenellenbogen, ... Breast Cancer Research and Treatment, 1-14, 2024 | 1 | 2024 |
| Outbreak of Respiratory Infection: nCoV-2019 Current Status and Its Impact on Global Health S Kumar, S Kumar, A Karim, K Bisht, A Ghani, VS Munda Current Respiratory Medicine Reviews 16 (3), 156-164, 2020 | 1 | 2020 |
| Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemotherapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade N Sharma, S Dey, S Singh, S Kumar, M Konar, P Naithani, R Panwar, ... Current Cancer Drug Targets, 2024 | | 2024 |
| COVID-19 Pandemic: Care for Indian Cancer Patients S Kumar Coronaviruses, 2020 | | 2020 |
Shalmoli BhattacharyyaPGIMER在 pgimer.edu.in 的电子邮件经过验证
